Helix BioPharma Corp.

TSX:HBP.TO

Biotechnology

Healthcare
$0.86 -4.70%

-$0.07 today

Market cap
$65.69M
Beta
-0.29
P/E (TTM)
-32.6
EPS (TTM)
-$0.04
52W Low $0.84High $5.40

Volume 0.00M

Average 0.00M

HBP.TO Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Helix BioPharma Corp.TSX: HBP.TO

Deferred Revenue · Q3 FY2026 · quarter ended Apr 2026

Deferred revenue remains negative

Q3 FY2026 deferred revenue was CA$0, compared with CA$0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterApr 2026
CA$0— QoQ
Last fiscal yearJul 2025
CA$0— YoY
Year agoApr 2025
CA$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

CAD · from the balance sheet

Latest · FY2025
0 CAD
Year-over-year change
—

Deferred Revenue vs competitors

How HBP.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Deferred revenue amounts to 0.0% of total assets for HBP.TO, versus a peer median of 0.0%.
HBP.TO Competitors
Deferred Revenue for HBP.TO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
HBP.TOHelix BioPharma Corp.Apr 2026CA$0 CAD——0.0%
MSCL.TOSatellos Bioscience Inc.Mar 2026$0 USD——0.0%
CRDL.TOCardiol Therapeutics Inc.Mar 2026CA$0 CAD——0.0%
HLS.TOHLS Therapeutics Inc.Mar 2026$0 USD——0.0%
SVA.TOSernova Corp.Apr 2026CA$0 CAD——0.0%
Peer median (excluding HBP.TO) ———0.0%

Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CAD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Cash & Equivalents3.57M3.25M808K1.08M65K
Short-term Investments00000
Net Receivables353K279K62K54K121K
Inventory0164K000
Other Current Assets0000223K
Total Current Assets4.02M3.7M996K1.46M409K
Property, Plant & Equipment (Net)47K35K33K33K4K
Goodwill00000
Intangible Assets0001K18.39M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets000(1K)0
Total Non-current Assets47K35K33K33K18.39M
Total Assets4.07M3.73M1.03M1.49M18.8M
Account Payables1.47M599K493K855K0
Short-term Debt2.03M2.47M00335K
Tax Payables00000
Deferred Revenue0345K000
Other Current Liabilities0(1K)998K02.88M
Total Current Liabilities3.87M3.41M1.87M1.58M3.22M
Long-term Debt1.58M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities1.58M0(1K)00
Total Liabilities5.46M3.41M1.87M1.58M3.22M
Common Stock139.66M147.51M152.07M158.57M179.29M
Retained Earnings(188.55M)(195.12M)(201.41M)(210.67M)(215.88M)
Accumulated OCI19.63M10.34M4.36M4.65M3.87M
Other Stockholders Equity0004.65M0
Minority Interest00000
Total Equity(1.39M)319K(844K)(90K)15.59M
Total Debt3.61M2.47M00335K
Net Debt47K(784K)(808K)(1.08M)270K

Helix BioPharma Corp.

TSX:HBP.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.